Administrative claims analysis of utilization and costs of care in health plan members with atopic dermatitis who had prior use of a topical corticosteroid and who initiate therapy with pimecrolimus or tacrolimus

Journal of Managed Care Pharmacy

Volumn 13, Issue 4, 2007, Pages 349-359

  Delea, Thomas E ^a   Gokhale, Manjusha ^b   Makin, Charles ^c   Hussein, Mohamed A ^d   Vanderpoel, Julie ^e   Sandman, Timothy ^f   Chang, Jane ^g   Sung, Jennifer ^g   Pinkston, Paul ^g   Gause, Douglas ^g   Jackson, J Mark ^h  

^a POLICY ANALYSIS INC PAI   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HEALTHCORE INC   (United States)

^d ValueMedics Research LLC   (United States)

^e CENTOCOR INC   (United States)

^f HUMANA INC   (United States)

^g NOVARTIS PHARMA AG   (Switzerland)

^h University of Louisville School of Medicine   (United States)

Author keywords

Atopic dermatitis; Costs; Pimecrolimus; Retrospective claims analysis; Tacrolimus

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; BETAMETHASONE VALERATE; CLOBETASOL PROPIONATE; FLUOCINOLONE ACETONIDE; FLUOCINONIDE; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENT; PIMECROLIMUS; TACROLIMUS; TRIAMCINOLONE ACETONIDE;

ADOLESCENT; ADULT; ARTICLE; ATOPIC DERMATITIS; CHILD; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG ANALYSIS; DRUG COST; DRUG USE; DRUG UTILIZATION; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MEDICAID; MEDICARE; PRESCRIPTION; REIMBURSEMENT; RETROSPECTIVE STUDY; UNITED STATES;

EID: 34250712401     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2007.13.4.349     Document Type: Article

References (40)

1. Leung DY, Bieber T. Atopic dermatitis. Lancet. 2003;361:151-60.
2. Schultz-Larson F, Hanifin JM. Epidemiology of atopic dermatitis. Immunol Allergy Clin North Am. 2002;22:1-24.
3. Taylor B, Wadsworth J, Wadsworth M, Peckham C. Changes in the reported prevalence of childhood eczema since the 1939-45 war. Lancet. 1984;2:1255-57.
4. Kiebert G, Sorensen SV, Revicki D, et al. Atopic dermatitis is associated with a decrement in health-related quality of life. Int J Dermatol. 2002;41(3):151-58.
5. Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity Acta Derm Venereol. 2000;80(6):430-34.
6. Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol. 1999;141(6):1067-75.
7. Ellis CN, Drake LA, Prendergast MM, et al. Cost of atopic dermatitis and eczema in the United States. J Am Acad Dermatol. 2002;46:361-70.
8. Fivenson D, Arnold RJ, Kaniecki DJ, Cohen JL, Frech F, Finlay AY. The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organization. J Manag Care Pharm. 2002;8(5):333-42. Available at: http://www.amcp.org/data/jmcp/Research-333342.pdf. Accessed April 21, 2007.
9. Johnson N, Kahler K. Total cost of care for patients with pediatric atopic dermatitis. Poster presented at: the American Academy of Dermatology 60th Annual Meeting; February 22-27, 2002; New Orleans, LA. Poster 121.
10. Su JC, Kemp AS, Varigos GA, Nolan TM. Atopic eczema: its impact on the family and financial cost. Arch Dis Child. 1997;76:159-62.
11. Lapidus CS, Schwarz DF, Honig PJ. Atopic dermatitis in children: who cares? who pays? J Am Acad Dermatol. 1993;28:699-703.
12. Fisher DA. Adverse effects of topical corticosteroid use. West J Med. 1995;162:123-26.
13. Kristmundsdottir F, David TJ. Growth impairment in children with atopic eczema. J R Soc Med. 1987;80:9-12.
14. Bode HH. Dwarfism following long-term topical corticosteroid therapy. JAMA. 1980;244:813-14.
15. Ellison JA, Patel L, Ray DW, David TJ, Clayton PE. Morning plasma cortisol levels in infants treated with topical fluorinated glucocorticosteroids. Pediatrics. 1980;65:103-06.
16. Paller AS, McAlister RO, Doyle JJ, Jackson A. Perceptions of physicians and pediatric patients about atopic dermatitis, its impact, and its treatment. Clin Pediatr. 2002;41:323-32.
17. Charman C, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic dermatitis. Br J Dermatol. 2000;142:931-36.
18. Weinberg JM. Formulary review of therapeutic alternatives for atopic dermatitis: focus on pimecrolimus. J Manag Care Pharm. 2005:11(1):56-64. Available at: http://www.amcp.org/data/jmcp/ Form_Manag_56-64.pdf. Accessed April 21, 2007.
19. Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safely and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol. 2002;46(4):495-504.
20. Meurer M, Folster-Holst R, Wozel G, et al; CAM-DE-01 Study Group. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology. 2002;205(3):271-77.
21. Hanifin JM, Ling MR, Langley R, Breneman D, Rafal E. Tacrolimus ointment for treatment of atopic dermatitis in adult patients: Part I, efficacy J Am Acad Dermatol. 2001;44(suppl 1):S28-S38.
22. Paller A, Eichenfield LF, Leung DY, Stewart D, Appell M. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol. 2001;44(suppl 1):S47-S57.
23. Boguniewicz M, Fiedler VC, Raimer S, et al. Pediatric Tacrolimus Study Group. A randomized vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. J Allergy Clin Immunol. 1998;102 (4 pt 1);555-57.
24. Ruzicka T, Bieber T, Schopf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med. 1997;337:816-21.
25. Kapp A, Papp K, Bingham A, et al. Flare Reduction in Eczema with Elidel (Infants) Multicenter Investigator Study Group. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroidal anti-inflammatory drug. J Allergy Clin Immunol. 2002; 110(2):277-84.
26. Wahn U, Bos JD, Goodfield M, et al. Flare Reduction in Eczema with Elidel (Children) Multicenter Investigator Study Group. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002;110(1 pt 1):e2.
27. Soter NA, Fleischer AB, Webster GF, Monroe E, Lawrence I. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part II, safety J Am Acad Dermatol. 2001;44(suppl 1):S39-S46.
28. Meingassner JG, Fahrngruber H, Bavandi A. Pimecrolimus inhibits the elicitation phase but does not suppress the sensitization phase in murine contact hypersensitivity, in contrast to tacrolimus and cyclosporine A. J Invest Dermatol. 2003;121(1):77-80. Erratum: J Invest Dermatol. 2003;121(5):1231.
29. Elidel [prescribing information]. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/elidel.pdf. Accessed June 2006.
30. Protopic [prescribing information]. Available at: http://www.astellas.us/ docs/protopic.pdf. Accessed June 2006.
31. FDA Public Health Advisory Available at: http://www.fda.gov/cder/drug/ advisory/elidel_paotopic.htm. Accessed June 2006.
32. Iskedjian M, Piwko C, Shear NH, Langley RG, Einarson TR. Topical calcineurin inhibitors in the treatment of atopic dermatitis: a meta-analysis of current evidence. Am J Clin Dermatol. 2004;5(4):267-79.
33. Kempers S, Boguniewicz M, Carter E, et al. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol. 2004;51(4):515-25.
34. Paller AS, Lebwohl M, Fleischer AB, et al. Tacrolimus ointment is more effective than pimecrolimus cream for patients with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatology. 2005;52(5):810-22.
35. Chang J, Sung J. Health plan budget impact analysis for pimecrolimus. J Manag Care Pharm. 2005;11(1):66-73. Available at: http://www.amcp.org/data/jmcp/Form_Manag_66-73.pdf. Accessed April 21, 2007.
36. Ellis CN, Kahler KH, Grueger J, Chang J. Cost effectiveness of management of mild-to-moderate atopic dermatitis with 1% pimecrolimus cream in children and adolescents 2-17 years of age. Am J Clin Dermatol. 2006;7(2):133-39.
37. Drug Facts and Comparisons 2004. Chicago, IL: Wolters Kluwer Health; 2004.
38. Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
39. Rubin DB. Estimating causal effects from large datasets using propensity scores. Ann Intern Med. 1997;127:757-63.
40. Parsons L. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. Proceedings of the 26th Annual SAS Users Group International Conference. Cary, NC: SAS Institute; 2001:214-26. Available at: http://support.sas.com/usergroups/sugi/proceedings/. Accessed April 2005.